Search research articles
Contact Us
Filters
Showing results (591-600 of 640) with videos related to
Page
of 64
Sort By:
Journal of Thrombosis and Haemostasis : JTH
|
October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years
Neil A Goldenberg, Sam Schulman, John M Kittelson, et al.
Journal of Thrombosis and Haemostasis : JTH
|
July 27, 2021
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
Walter Ageno, Renato D Lopes, Mark Goldin, et al.
Circulation
|
April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials
Alex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.
Pediatrics
|
April 29, 2022
Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial
Anthony A Sochet, John M Morrison, Julie Jaffray, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 30, 2015
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings
N A Goldenberg, T Abshire, P J Blatchford, et al.
Circulation
|
February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)
Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
Chest
|
August 14, 2022
Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline
James D Douketis, Alex C Spyropoulos, M Hassan Murad, et al.
Lancet Regional Health. Americas
|
June 27, 2023
Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study
Caroline Cândida Carvalho de Oliveira, Leandro Barile Agati, Camilla Moreira Ribeiro, et al.
Pilot and Feasibility Studies
|
November 4, 2025
Models of housing and support to reduce risks of COVID-19 infection and homelessness: the moving on pilot randomised controlled trial
Peter Mackie, Elizabeth Randell, Calie Dyer, et al.
JAMA
|
January 11, 2022
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial
Neil A Goldenberg, John M Kittelson, Thomas C Abshire, et al.
Page
of 64
Search research articles
Search
Showing results (591-600 of 640) with videos related to
Sort By:
Page
of 64
Journal of Thrombosis and Haemostasis : JTH
|
October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years
Neil A Goldenberg, Sam Schulman, John M Kittelson, et al.
Journal of Thrombosis and Haemostasis : JTH
|
July 27, 2021
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
Walter Ageno, Renato D Lopes, Mark Goldin, et al.
Circulation
|
April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials
Alex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.
Pediatrics
|
April 29, 2022
Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial
Anthony A Sochet, John M Morrison, Julie Jaffray, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 30, 2015
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings
N A Goldenberg, T Abshire, P J Blatchford, et al.
Circulation
|
February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)
Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
Chest
|
August 14, 2022
Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline
James D Douketis, Alex C Spyropoulos, M Hassan Murad, et al.
Lancet Regional Health. Americas
|
June 27, 2023
Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study
Caroline Cândida Carvalho de Oliveira, Leandro Barile Agati, Camilla Moreira Ribeiro, et al.
Pilot and Feasibility Studies
|
November 4, 2025
Models of housing and support to reduce risks of COVID-19 infection and homelessness: the moving on pilot randomised controlled trial
Peter Mackie, Elizabeth Randell, Calie Dyer, et al.
JAMA
|
January 11, 2022
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial
Neil A Goldenberg, John M Kittelson, Thomas C Abshire, et al.
Page
of 64